MD Anderson and Exscientia launch strategic collaboration to leverage AI in developing novel oncology treatments
Â鶹ӳ» MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence (AI) capabilities of Exscientia in order to advance novel small-molecule oncology therapies.
The research collaboration will utilize Exscientia’s precision medicine platform to identify novel anti-cancer...
Eyal Gottlieb, Ph.D., to join MD Anderson as Vice President for Research
Â鶹ӳ» MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
MD Anderson Research Highlights: SITC 2022 Special Edition
´¡µþ³§°Õ¸é´¡°ä°Õ³§:Ìý374,Ìý568,Ìý590,Ìý657,Ìý659,Ìý782
Â鶹ӳ»Â MD Anderson Cancer Center’s...